Clinical trialPhase 2Recruiting

Durvalumab and Oleclumab in Resectable PDAC

Durvalumab and Oleclumab in Resectable PDAC: A Window of Opportunity Study (DORA Trial)

NCT06060405 ↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome: Ongoing
Phase: Phase 2
Status: Recruiting
Study type: Interventional
Start: 29 November 2023
Expected end: 30 October 2026
Enrollment: 22 participants
Sites: 1
Primary outcomes: Percent change in CD8+ cell infiltration
Sponsor: Other
Results posted: No
Last update: 23 June 2026

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a multi-site Canadian, window of opportunity study to evaluate the immune activity of durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma (PDAC) when given prior to surgery.